Molecular structure of Carfilzomib, CAS Number: 868540-17-4
Carfilzomib (CAS 868540-17-4)
Alternate Names:
PR-171
Application:
Carfilzomib, Free Base is a potent, specific ChT-L proteasome inhibitor
CAS Number:
868540-17-4
Molecular Weight:
719.91
Molecular Formula:
C40H57N5O7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Carfilzomib, Free Base, is a potent, specific chymotrypsin-like (ChT-L) proteasome inhibitor. Carfilzomib has been shown to inhibit the immunoproteasome activities in the β5 subunit (>80% inhibition at concentrations ≥10 nM), but does not appear to inhibit the postglutamyl peptide hydrolyzing (PGPH) activity of the β1 subunit or the trypsin-like (T-L) activity in the β2 subunit (using in vitro doses of ≤100 nM). Further, carfilzomib has been shown to inhibit the proliferation of IL-6-independent and -dependent myeloma cell lines (IC50 of
Carfilzomib (CAS 868540-17-4) References
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. | Stewart, AK., et al. 2015. N Engl J Med. 372: 142-52. PMID: 25482145
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Shah, JJ., et al. 2015. Blood. 126: 2284-90. PMID: 26384354
- Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. | Chari, A., et al. 2019. Blood. 134: 421-431. PMID: 31113777
- Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. | Landgren, O., et al. 2019. Leukemia. 33: 2127-2143. PMID: 31341235
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. | Dimopoulos, M., et al. 2020. Lancet. 396: 186-197. PMID: 32682484
- Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. | Touzeau, C., et al. 2021. Future Oncol. 17: 993-998. PMID: 33289427
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. | Moreau, P., et al. 2021. Lancet. 397: 2361-2371. PMID: 34097854
- Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). | Pennipede, D., et al. 2021. Eur J Haematol. 107: 602-608. PMID: 34378251
- Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. | Banerjee, R., et al. 2021. Future Oncol. 17: 4849-4860. PMID: 34553603
- Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. | Usmani, SZ., et al. 2023. Blood Adv. 7: 3739-3748. PMID: 37163358
Inhibitor of:
β-2-Microglobulin, 20S Proteasome α1, 20S Proteasome α2, 20S Proteasome α3, 20S Proteasome α7, 20S Proteasome α8, 20S Proteasome β1, 20S Proteasome β5, 20S Proteasome β7, 26S Proteasome, 26S Proteasome p42C, 26S Proteasome p48A, 26S Proteasome p50, 26S Proteasome p54, 26S Proteasome p58, 4931431F19Rik, 4933402E13Rik, 4933422H20Rik, 9930039A11Rik, ADAM, ADAM9, APC10, APC11, APC2, APC4, Apg12, ARIH1, ASB-11, ASB-2, AV320801, BTBD2, BTBD6, C1orf112, C1QDC2, C6orf113, CCP5, Cdc23, Cdc34B, CKR-8, CRBN, CSN7a, CSN7b, Dcun1D1, Dcun1D5, Dda1, DDI2, Derlin-1, DET1, Dorfin, DTWD1, E2ig5, E330034G19Rik, EG382106, EG382156, EG668359, EndoV, FBXO21, FBXO41, Fbxw12, FBXW23, FLJ44815, Gigaxonin, Glomulin, Gm514, GMCL1L, GP78-1, GPR172C, HECTD4, Herc1, Herc2, Ig κ chain, Ig κ light chain, Ikaros, IQUB, Josephin-2, Josephin-3, KBTBD4, KBTBD5, KCMF1, Kex2, KIAA1683, KIAA1984, KLHDC2, KLHDC3, KLHDC4, KLHDC6, KLHL32, KLHL33, LNX1, LOC100041274, LONRF1, LONRF3, MAGE-L2, Makorin-2, MECL-1, MIB1, MuRF2, NEDL1, NEURL4, NHLRC3, NOB1P, Nulp1, Nup62-il4i1, Olr1124, Olr559, Olr697, Olr750, OTC, PA, PA200, PARC, PCNP, PI-9, PIH1D2, PJA1, PJA2, Plasma Cell, PLIC-1, POT1, Proteassemblin, PSMB11, PSMB4, PSMB6, PSMC2, PSMC3, PSMC4, PSMC6, PSMD11, PSMD12, PSMD13, PSMD3, PSMD5, PSMD7, PSMD8, PSME proteasome activator subunits (PA28), QRICH2, Rad23, RBMXL2, Rbx2, RING1B, RMND5B, RNF103, RNF113A, RNF113A1, RNF113A2, RNF121, RNF130, RNF150, RNF152, RNF166, RNF180, RNF182, RNF187, RNF207, RNF214, RNF219, RNF24, RNF32, RNF5, Rpn11, SEL-10, SHARPIN (SHANK associated RH domain interactor), SHFM3, Slimb, SPCS3, SUG1, TIP120B, TRIM11, TRIM23, TRIM31, TRIM37, TRIM40, TRIM45, TRIM47, TRIP15, Ub, UBC2, UBCE7IP4, UBE1L, UBE1L2, UBE2CBP, UBE2Z, UBE3B, UBE3C, UBE4A, UBQLN3, UBQLNL, Ubr2, UBXD7, UFD1, USP21, USP29, V1RH5, Vta1, WDR20a, ZFAND1, ZFAND2B, ZFP91, ZNF114, ZNF121, and ZNF264.Activator of:
20S Proteasome α4, 20S Proteasome α5, 20S Proteasome α6, 26S Proteasome α, A1Up, ADRM1, ASB-7, BLOS2, CRLF3, CUL-7, Dcun1D3, Derlin-3, ECM29, FBL12, FBL13, Fbxo12J, FBXO30, FBXO35, FBXO7, Fbxw13, HSPA12B, Neuralized-2, PI31, POH1, PSMD2, PSMD8, Rad23A, RNF113B, SVIP, TRC8, TRIP12, UBAP1, UBC8, UBE2J2, UBE2S, UCH-L3, USP38, and USP42.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Carfilzomib, 5 mg | sc-396755 | 5 mg | $41.00 |